AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10965637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 145
Study 10965637 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 145
Study 8985850 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solution (45 mL/1.7 m2/dose)
Number of subjects: 34
Study 8985850 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol-based solution (4 L/1.7 m2)
Number of subjects: 34
Study 1335979 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 23
Study 1335979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6525441 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of prednisone as a reference solution or as a tablet in a 6‐week, six‐way crossover design
Number of subjects: 18
Study 6525441 — intervention group
Group type: COMPARATOR
Intervention: Dissolution tests on five commercial tablet forms
Number of subjects: 18
Study 31551229 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC catheter parenteral nutrition support
Number of subjects: 140
Study 31551229 — intervention group
Group type: COMPARATOR
Intervention: Central venous catheter (CVC) nutrition support
Number of subjects: 140
Study 29270612 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct therapy for 8 to 12 weeks
Number of subjects: 114
Study 29270612 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect therapy for 8 to 12 weeks
Number of subjects: 114
Study 29270612 — intervention group
Group type: COMPARATOR
Intervention: Direct therapy
Number of subjects: 114
Study 29270612 — intervention group
Group type: COMPARATOR
Intervention: Both therapies
Number of subjects: 114
Study 26818059 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration PAP
Number of subjects: 17
Study 26818059 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week PAP therapy
Number of subjects: 17
Study 26818059 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 17
Study 25579524 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron beam therapy (16 Gy in 8 fractions)
Number of subjects: 50
Study 25579524 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT) (16 Gy in 8 fractions)
Number of subjects: 50
Study 25579524 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (Electron and 3DCRT)
Number of subjects: 50
Study 25579524 — intervention group
Group type: COMPARATOR
Intervention: 3DCRT
Number of subjects: 50
Study 22279526 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral priming with experimenters believing participants would walk slower
Number of subjects: 0
Study 22279526 — intervention group
Group type: COMPARATOR
Intervention: Behavioral priming with experimenters believing participants would walk faster
Number of subjects: 0
Study 19207632 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) training, 36 sessions
Number of subjects: 102
Study 19207632 — intervention group
Group type: COMPARATOR
Intervention: Computerised attention skills training (control)
Number of subjects: 102
Study 17015004 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-D (distance measured from bronchial orifice to lesion); 57 patients
Number of subjects: 113
Study 17015004 — intervention group
Group type: COMPARATOR
Intervention: EBUS (biopsy forceps advanced regardless of distance); 56 patients
Number of subjects: 113
Study 14698542 — intervention group
Group type: COMPARATOR
Intervention: MVP regimen (Mitomycin-C 8 mg/m2 d1, Vinblastine 4 mg/m2 d 1-8, Cisplatin 100 mg/m2 d1)
Number of subjects: 153
Study 14698542 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC regimen (Mitomycin-C 8 mg/m2 d1, Vinblastine 4 mg/m2 d 1-8, Carboplatin 300 mg/m2 d1)
Number of subjects: 153
Study 11533519 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil (600 mg once daily) for 12 months
Number of subjects: 80
Study 11533519 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 80
Study 9829381 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoguided surgery (RIGS) with Iodine‐125 labeled monoclonal antibodies (MoAbs) B72.3 anti‐TAG
Number of subjects: 21
Study 9829381 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoguided surgery (RIGS) with FO23C5 anti‐carcinoembryonic antigen (CEA)
Number of subjects: 21
Study 8035029 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin
Number of subjects: 10
Study 8035029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2660872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultamicillin
Number of subjects: 426
Study 2660872 — intervention group
Group type: COMPARATOR
Intervention: Bacampicillin
Number of subjects: 426
Study 4929367 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.5 mg/kg/day) and Prednisone (20 mg/day for adults, 0.5 mg/kg/day for children)
Number of subjects: 149
Study 4929367 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 149
Study 31537557 — intervention group
Group type: COMPARATOR
Intervention: Standard service with a smartphone for outcome measurement only
Number of subjects: 72
Study 31537557 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard service plus a smartphone including the motivational smartphone app
Number of subjects: 72
Study 28114993 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview administration of the EuroQol Health Related Quality of Life survey
Number of subjects: 90
Study 28114993 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-completed form administration of the EuroQol Health Related Quality of Life survey
Number of subjects: 90
Study 28114993 — intervention group
Group type: COMPARATOR
Intervention: Both methods of administration (telephone and patient-completed)
Number of subjects: 90
Study 26007221 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC group (6 hours of didactic lectures and 8 hours of virtual reality simulation-based training with expert feedback)
Number of subjects: 33
Study 26007221 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC group
Number of subjects: 33
Study 26007221 — intervention group
Group type: COMPARATOR
Intervention: SRL group (self-regulated learning with 8 hours of simulator practice)
Number of subjects: 33
Study 23225897 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment in infants (IPTi) with sulfadoxine‐pyrimethamine (SP) administered at 2, 3, and 9 months of age
Number of subjects: 0
Study 23225897 — intervention group
Group type: COMPARATOR
Intervention: Comparison areas without IPTi
Number of subjects: 0
Study 20473880 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-type liposarcoma cases (n=8)
Number of subjects: 8
Study 20473880 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 8
Study 19487704 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention to improve breastfeeding knowledge and attitudes
Number of subjects: 551
Study 19487704 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 551
Study 16919749 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected diacetylmorphine (DAM) plus oral methadone (average DAM dosage: 274.5 mg/day; average methadone dosage: 42.6 mg/day) for 9 months
Number of subjects: 62
Study 16919749 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone (average dosage: 105 mg/day) for 9 months
Number of subjects: 62
Study 15788738 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine supplementation (8.5 g for 4 weeks)
Number of subjects: 26
Study 15788738 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous supplement (control)
Number of subjects: 26
Study 11883986 — intervention group
Group type: EXPERIMENTAL
Intervention: Task switching with instructional cues
Number of subjects: 0
Study 11883986 — intervention group
Group type: EXPERIMENTAL
Intervention: Task switching
Number of subjects: 0
Study 10462426 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom usage during sexual intercourse
Number of subjects: 0
Study 10462426 — intervention group
Group type: COMPARATOR
Intervention: No condom usage during sexual intercourse
Number of subjects: 0
Study 7790242 — intervention group
Group type: EXPERIMENTAL
Intervention: 67.2 Gy
Number of subjects: 399
Study 7790242 — intervention group
Group type: EXPERIMENTAL
Intervention: 72.0 Gy
Number of subjects: 399
Study 7790242 — intervention group
Group type: EXPERIMENTAL
Intervention: 76.8 Gy
Number of subjects: 399
Study 7790242 — intervention group
Group type: EXPERIMENTAL
Intervention: 81.6 Gy
Number of subjects: 399
Study 7790242 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interfraction interval <= 4.5 h
Number of subjects: 399
Study 7790242 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interfraction interval > 4.5 h
Number of subjects: 399
Study 2400374 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation on a central target
Number of subjects: 45
Study 2400374 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted visual field (15 degrees)
Number of subjects: 45
Study 2400374 — intervention group
Group type: COMPARATOR
Intervention: Control group (entire visual field, no fixation)
Number of subjects: 45
Study 410053 — intervention group
Group type: EXPERIMENTAL
Intervention: DA antagonist (droperidol)
Number of subjects: 6
Study 410053 — intervention group
Group type: EXPERIMENTAL
Intervention: ACh agonist (physostigmine)
Number of subjects: 6
Study 410053 — intervention group
Group type: EXPERIMENTAL
Intervention: Deanol
Number of subjects: 6
Study 410053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31206748 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised Controlled Trials (RCTs)
Number of subjects: 0
Study 31206748 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational Studies (OP)
Number of subjects: 0
Study 28867267 — intervention group
Group type: EXPERIMENTAL
Intervention: One4All intervention
Number of subjects: 478
Study 28867267 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 478
Study 25156527 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered secondhand smoke intervention involving 3 home visits in the first 3 months of the infants' lives (plus usual care)
Number of subjects: 293
Study 25156527 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 293
Study 22532236 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher amount of physical exercise
Number of subjects: 1292
Study 22532236 — intervention group
Group type: EXPERIMENTAL
Intervention: High motivation and retirement
Number of subjects: 1292
Study 21944629 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Hepatectomy
Number of subjects: 95
Study 21944629 — intervention group
Group type: COMPARATOR
Intervention: Other Procedures
Number of subjects: 95
Study 19857081 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavocoxid 250 mg twice a day
Number of subjects: 59
Study 19857081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17280748 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine with QS21 adjuvant
Number of subjects: 30
Study 17280748 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine without QS21 adjuvant
Number of subjects: 30
Study 14982478 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation to the scalp for tinea capitis
Number of subjects: 0
Study 14982478 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dosimetry accounting for uncertainties
Number of subjects: 0
Study 11557467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (10 mg/kg every 8 h for 14 days) followed by oral acyclovir (800 mg q6h for 42 days)
Number of subjects: 10
Study 9782813 — intervention group
Group type: EXPERIMENTAL
Intervention: Futuro wrist orthosis
Number of subjects: 10
Study 9782813 — intervention group
Group type: COMPARATOR
Intervention: ThermoLyn wrist orthosis
Number of subjects: 10
Study 8147630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwashed shed mediastinal blood (group 1; n = 16)
Number of subjects: 32
Study 8147630 — intervention group
Group type: COMPARATOR
Intervention: Liquid preserved packed red blood cells (group 2; n = 16)
Number of subjects: 32
Study 2842266 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) administered subcutaneously, 7,500 anti activated factor X Units once a day for 7 days
Number of subjects: 173
Study 2842266 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin (CH) administered subcutaneously, 5,000 International Units t.i.d. for 7 days
Number of subjects: 173
Study 31808656 — intervention group
Group type: COMPARATOR
Intervention: Intravenous opioid with 1 mg/kg tramadol HCl (Group O)
Number of subjects: 40
Study 31808656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided quadratus lumborum block (Group B)
Number of subjects: 40
Study 30747501 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy (50 mg subcutaneous weekly)
Number of subjects: 851
Study 30747501 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy (20 mg oral weekly)
Number of subjects: 851
Study 30747501 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Etanercept 50 mg subcutaneous weekly + Methotrexate 20 mg oral weekly)
Number of subjects: 851
Study 30747501 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy and Combination therapy
Number of subjects: 851
Study 28628970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankascin 568 (500 mg capsules, 2 capsules daily for 8 weeks)
Number of subjects: 0
Study 28628970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25043476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HPV positivity during the first screening round
Number of subjects: 1000
Study 25043476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HPV positivity during the second screening round
Number of subjects: 1000
Study 25043476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HPV positivity during the third screening round
Number of subjects: 1000
Study 25043476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HPV positivity for >9 years of follow-up
Number of subjects: 1000
Study 25043476 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18/31/33
Number of subjects: 1000
Study 25043476 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV35/45/52/58
Number of subjects: 1000
Study 25043476 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV39/51/56/59/66/68
Number of subjects: 1000
Study 25043476 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 1000
Study 25043476 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18/31/33/45/52/58
Number of subjects: 1000
Study 25043476 — intervention group
Group type: EXPERIMENTAL
Intervention: All high-risk HPV types
Number of subjects: 1000
Study 23281147 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A dilution of 100 U in 1 ml of saline (Group A)
Number of subjects: 10
Study 23281147 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX‐A dilution of 100 U in 2 ml of saline (Group B)
Number of subjects: 10
Study 21474843 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 96
Study 21474843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 18972731 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion
Number of subjects: 85
Study 18972731 — intervention group
Group type: COMPARATOR
Intervention: Chinese drug
Number of subjects: 85
Study 16242900 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of clinical supervision
Number of subjects: 61
Study 16242900 — intervention group
Group type: COMPARATOR
Intervention: No clinical supervision (control group)
Number of subjects: 61
Study 12717239 — intervention group
Group type: EXPERIMENTAL
Intervention: eCsA (CsA elimination)
Number of subjects: 133
Study 12717239 — intervention group
Group type: COMPARATOR
Intervention: mCsA (CsA dose minimization)
Number of subjects: 133
Study 12717239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (eCsA and mCsA)
Number of subjects: 133
Study 10856412 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart abstraction
Number of subjects: 20
Study 10856412 — intervention group
Group type: COMPARATOR
Intervention: Standardized-patient checklist
Number of subjects: 20
Study 9382004 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial approach
Number of subjects: 50
Study 9382004 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 50
Study 1608680 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 218
Study 1608680 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin and metronidazole
Number of subjects: 218
Study 3985516 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education (2-hour educational program)
Number of subjects: 103
Study 3985516 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 103
Study 3985516 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education in multitopic and unitopic contexts
Number of subjects: 103
Study 3985516 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing medical education (all groups)
Number of subjects: 103
Study 30406325 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilting sutures (Group B)
Number of subjects: 370
Study 30406325 — intervention group
Group type: COMPARATOR
Intervention: No quilting sutures (Group A)
Number of subjects: 370
Study 28855183 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tailored advice (TrailS6)
Number of subjects: 232
Study 28855183 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 232
Study 27611748 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning stent
Number of subjects: 30
Study 27611748 — intervention group
Group type: COMPARATOR
Intervention: Control (no positioning stent)
Number of subjects: 30
Study 24383431 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy diet without cereal grains and dairy products
Number of subjects: 15
Study 21482060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 88
Study 21482060 — intervention group
Group type: COMPARATOR
Intervention: Written warnings
Number of subjects: 88
Study 20093665 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 43
Study 20093665 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 43
Study 20093665 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AIT and ST (COM)
Number of subjects: 43
Study 20093665 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 19368299 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality protein maize (QPM)
Number of subjects: 48
Study 19368299 — intervention group
Group type: COMPARATOR
Intervention: Conventional maize
Number of subjects: 48
Study 16470490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PD 123319 (10 mcg/minute for 5 minutes)
Number of subjects: 16
Study 16470490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12419114 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care (HC) offered at the moment of AIDS diagnosis
Number of subjects: 0
Study 12419114 — intervention group
Group type: COMPARATOR
Intervention: Home care (HC) offered six months from diagnosis (Control Group)
Number of subjects: 0
Study 11532889 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal responses
Number of subjects: 0
Study 11532889 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual responses
Number of subjects: 0
Study 11532889 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial processing
Number of subjects: 0
Study 11532889 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal processing
Number of subjects: 0
Study 9222631 — intervention group
Group type: EXPERIMENTAL
Intervention: Great auricular nerve preserved
Number of subjects: 31
Study 9222631 — intervention group
Group type: COMPARATOR
Intervention: Great auricular nerve sacrificed
Number of subjects: 31
Study 7690383 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg three times daily
Number of subjects: 97
Study 7690383 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 5 mg three times daily
Number of subjects: 97
Study 7690383 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine 2.5 mg three times daily
Number of subjects: 97
Study 7690383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 3319543 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 622
Study 3319543 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 622
Study 3319543 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 622
Study 3319543 — intervention group
Group type: EXPERIMENTAL
Intervention: Primidone
Number of subjects: 622
Study 3319543 — intervention group
Group type: EXPERIMENTAL
Intervention: All four drugs combined
Number of subjects: 622
Study 3319543 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine and Phenytoin
Number of subjects: 622
Study 3319543 — intervention group
Group type: COMPARATOR
Intervention: Behavioral toxicity battery
Number of subjects: 622
Study 29169968 — intervention group
Group type: EXPERIMENTAL
Intervention: HP35% hydrogen peroxide
Number of subjects: 25
Study 29169968 — intervention group
Group type: COMPARATOR
Intervention: HP15% hydrogen peroxide
Number of subjects: 25
Study 28208819 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper version of the Canadian Diet History Questionnaire II (CDHQ‐II)
Number of subjects: 648
Study 28208819 — intervention group
Group type: EXPERIMENTAL
Intervention: Web version of the Canadian Diet History Questionnaire II (CDHQ‐II)
Number of subjects: 648
Study 28208819 — intervention group
Group type: COMPARATOR
Intervention: Web version of the CDHQ‐II
Number of subjects: 648
Study 28208819 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the CDHQ‐II
Number of subjects: 648
Study 24131370 — intervention group
Group type: EXPERIMENTAL
Intervention: Neater Uni‐wheelchair
Number of subjects: 4